Salim Yusuf
Telmisartan to prevent recurrent stroke and cardiovascular events
Yusuf, Salim; Diener, Hans-Christoph; Sacco, Ralph L.; Cotton, Daniel; Ounpuu, Stephanie; Lawton, William A.; Palesch, Yuko; Martin, Renée H.; Albers, Gregory W.; Bath, Philip M.W.; Bornstein, Natan; Chan, Bernard P.L.; Chen, Sien-Tsong; Cunha, Luis; Dahlöf, Björn; De Keyser, Jacques; Donnan, Geoffrey A.; Estol, Conrado; Gorelick, Philip; Gu, Vivian; Hermansson, Karin; Hillbrich, Lutz; Kaste, Markku; Lu, Chuanzhen; Machnig, Thomas; Pais, Prem; Roberts, Robin; Skvortsova, Veronika; Teal, Philip; Toni, Danilo; Vandermaelen, Cam; Voight, Thor; Weber, Michael; Yoon, Byung-Woo
Authors
Hans-Christoph Diener
Ralph L. Sacco
Daniel Cotton
Stephanie Ounpuu
William A. Lawton
Yuko Palesch
Renée H. Martin
Gregory W. Albers
Philip M.W. Bath
Natan Bornstein
Bernard P.L. Chan
Sien-Tsong Chen
Luis Cunha
Björn Dahlöf
Jacques De Keyser
Geoffrey A. Donnan
Conrado Estol
Philip Gorelick
Vivian Gu
Karin Hermansson
Lutz Hillbrich
Markku Kaste
Chuanzhen Lu
Thomas Machnig
Prem Pais
Robin Roberts
Veronika Skvortsova
Philip Teal
Danilo Toni
Cam Vandermaelen
Thor Voight
Michael Weber
Byung-Woo Yoon
Abstract
Background
Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent
stroke. In addition, inhibition of the renin–angiotensin system in high-risk patients
reduces the rate of subsequent cardiovascular events, including stroke. However, the
effect of lowering of blood pressure with a renin–angiotensin system inhibitor soon
after a stroke has not been clearly established. We evaluated the effects of therapy
with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke.
Methods
In a multicenter trial involving 20,332 patients who recently had an ischemic stroke,
we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to receive
placebo. The primary outcome was recurrent stroke. Secondary outcomes were
major cardiovascular events (death from cardiovascular causes, recurrent stroke,
myocardial infarction, or new or worsening heart failure) and new-onset diabetes.
Results
The median interval from stroke to randomization was 15 days. During a mean followup
of 2.5 years, the mean blood pressure was 3.8/2.0 mm Hg lower in the telmisartan
group than in the placebo group. A total of 880 patients (8.7%) in the telmisartan group
and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in
the telmisartan group, 0.95; 95% confidence interval [CI], 0.86 to 1.04; P = 0.23). Major
cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and
1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01;
P = 0.11). New-onset diabetes occurred in 1.7% of the telmisartan group and 2.1% of the
placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P = 0.10).
Conclusions
Therapy with telmisartan initiated soon after an ischemic stroke and continued for
2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular
events, or diabetes. (ClinicalTrials.gov number, NCT00153062.)
Journal Article Type | Article |
---|---|
Publication Date | Aug 27, 2008 |
Journal | New England Journal of Medicine |
Print ISSN | 0028-4793 |
Electronic ISSN | 0028-4793 |
Publisher | Massachusetts Medical Society |
Peer Reviewed | Peer Reviewed |
Volume | 359 |
Issue | 12 |
APA6 Citation | Yusuf, S., Diener, H., Sacco, R. L., Cotton, D., Ounpuu, S., Lawton, W. A., …Yoon, B. (2008). Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine, 359(12), doi:10.1056/NEJMoa0804593 |
DOI | https://doi.org/10.1056/NEJMoa0804593 |
Publisher URL | http://content.nejm.org/cgi/content/full/359/12/1225 |
Copyright Statement | Copyright information regarding this work can be found at the following address: http://eprints.nottingh.../end_user_agreement.pdf |
Files
Yusuf_NEJM_20080827.pdf
(469 Kb)
PDF
Copyright Statement
Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf